Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin Treatment

Adam Whaley-Connell, Javad Habibi, Ravi Nistala, Shawna A. Cooper, Poorna R. Karuparthi, Melvin R. Hayden, Nathan Rehmer, Vincent G. DeMarco, Bradley T. Andresen, Yongzhong Wei, Carlos Ferrario, James R. Sowers

Abstract—Activation of reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase by angiotensin II is integral to the formation of oxidative stress in the vasculature and the kidney. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibition is associated with reductions of oxidative stress in the vasculature and kidney and associated decreases in albuminuria. Effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibition on oxidative stress in the kidney and filtration barrier integrity are poorly understood. To investigate, we used transgenic TG(mRen2)27 (Ren2) rats, which harbor the mouse renin transgene and renin-angiotensin system activation, and an immortalized murine podocyte cell line. We treated young, male Ren2 and Sprague-Dawley rats with rosuvastatin (20 mg/kg IP) or placebo for 21 days. Compared with controls, we observed increases in systolic blood pressure, albuminuria, renal NADPH oxidase activity, and 3-nitrotyrosine staining, with reductions in the rosuvastatin-treated Ren2. Structural changes on light and transmission electron microscopy, consistent with periartrial fibrosis and podocyte foot-process effacement, were attenuated with statin treatment. Nephrin expression was diminished in the Ren2 kidney and tended to normalize with statin treatment. Angiotensin II–dependent increases in podocyte NADPH oxidase activity and subunit expression with resultant reactive oxygen species formation in the kidney and podocyte. Furthermore, statin attenuation of NADPH oxidase activation and reactive oxygen species formation in the kidney/podocyte seems to play roles in the abrogation of oxidative stress-induced filtration barrier injury and consequent albuminuria. (Hypertension. 2008;51[part 2]:474-480.)

Key Words: angiotensin II ■ albuminuria ■ glomerular filtration barrier ■ transgenic Ren2 rat ■ rosuvastatin

Renin-angiotensin system (RAS) activation and subsequently elevated angiotensin II (Ang II) exert the pressor, proliferative, profibrotic, and proinflammatory actions.1–3 Activation of tissue reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase seems to contribute to deleterious actions, such as oxidative stress and endothelial dysfunction manifesting as hypertension, albuminuria, and progressive glomerular dysfunction, that may ultimately lead to chronic kidney disease.1,4 There is accumulating evidence that tissue-based RAS further modulates cell growth, metabolism, and tissue remodeling.5,6

Evidence for a local RAS in the glomerulus raises the prospect of NADPH oxidase–induced podocyte and filtration barrier injury.7,8 Furthermore, in vitro protein exposure, mechanical stretch, and glomerular hypertension enhance tissue Ang II production, which may potentiate the impact of elevated blood pressure on glomerular injury manifesting as albuminuria.9,10 Previous work related to the pathogenesis of albuminuria delineated abnormalities such as basement membrane thickening, loss of the slit-pore diaphragm integrity, and widening of the podocyte foot process base width.11 Recent evidence characterized foot process effacement and loss of the slit-pore diaphragm as critical in decreasing filtration barrier integrity.12

3-Hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors (statins) exert beneficial actions on oxidative stress and endothelial dysfunction independent of their cholesterol-lowering properties. Many of the actions of statins are thought to be mediated by decreasing reactive oxygen species (ROS) formation in various tissues.13 ROS derived from NADPH oxidase activation have been shown to play a critical role in hypertrophy, fibrosis, and remodeling in the heart and vasculature.14–16 NADPH oxidase is a multi-component enzyme complex that is composed of the...
membrane-bound heterodimer gp91phox (phox indicates phagocytic oxidase; NOX2) and its homologue NOX4; p22phox, the cytosolic regulatory subunits p40phox, p47phox, and p67phox, and the small GTP-binding protein, Rac1.14,15 Statins reduce cellular levels of isoprenoids and inhibit the subsequent isoprenylation of small G proteins such as Rac.17,18 Accordingly, we evaluated the impact of statin treatment on increases in NADPH oxidase activity and contemporaneously on the glomerular filtration barrier and podocyte integrity. We used the transgenic TG(mRen2)27 (Ren2) rat with the mouse renin transgene and RAS activation, as well as an immortalized murine podocyte cell line. We hypothesized that Ang II stimulation of NADPH oxidase would contribute to glomerular filtration barrier remodeling and the podocyte generation of ROS. We further hypothesized that the beneficial effects of statin therapy would be mediated in part through reductions in NADPH oxidase activation and generation of ROS.

**Materials and Methods**

**Animals and Treatments**

All of the animal procedures were approved by the institutional animal care and use committees at the University of Missouri Harry S. Truman Veterans’ Affairs Medical Center and housed in accordance with National Institutes of Health guidelines. Ren2 (5- to 6-week–old) and age-matched Sprague-Dawley (SD) male rats were randomly assigned to placebo-treated control (Ren2-C and SD-C, respectively; n = 6 each) or rosuvastatin (AstraZeneca) treatment groups (Ren2-RSV and SD-RSV, respectively; n = 4 each). Rosuvastatin (20 mg/kg per day) in saline or an equal volume of saline was administered intraperitoneally to the rosuvastatin or control groups, respectively, for 21 days.

**Systolic Blood Pressure and Albuminuria**

Details of systolic blood pressure (SBP) and albuminuria are available in a data supplement available online at http://hyper.ahajournals.org. Briefly, SBP was determined at the end of rosuvastatin treatment on days 19 or 20 using the tail cuff after acclimatization and restraint conditioning for 48 hours on each group of rats (SDC, n = 6; SD-RSV, n = 4; Ren2-C, n = 6; Ren2-RSV, n = 4). As measured at the end of the treatment period, there were increases in SBP in Ren2 (9.7 mm Hg; P < 0.05) compared with SD controls (9.8 mm Hg; P = 0.13) when compared with SD controls (156.0 ± 9.8 mm Hg; P < 0.05) without reductions in rosuvastatin-treated animals (202 ± 4.5 mm Hg and 159.7 ± 9.7 mm Hg, respectively; Figure 1A).

**Transmission Electron Microscopy Methods**

Details of the transmission electron microscopy (TEM) in this study are available in the data supplement. Briefly, kidney cortical tissue from each group of rats (SDC, n = 6; SD-RSV, n = 4; Ren2-C, n = 6; Ren2-RSV, n = 4) was prepared12–19 and evaluated for nephrin C-17, gp91phox (NOX2; 5'-CCA ACT GGT ATG AGT trichloroacetic acid (TCA)-3') and reverse (5'-GAG AGT TTC AGC CAA GGC TTC-3') and Rac1.20 Expression levels were normalized using 18S as the control.

**Immunofluorescent Studies**

Details of the immunofluorescent studies are available in the data supplement. Briefly, harvested kidney cortical tissue from each group of rats (SDC, n = 4; SD-RSV, n = 4; Ren2-C, n = 4; Ren2-RSV, n = 4) was prepared13–16 and evaluated for nephrin with 2 antibodies (N-20 and C-17); total protein was stained with amido-black staining to normalize the data.

**Western Blot Analysis**

Details of the Western blot analysis are available in the data supplement. Briefly, kidney cortical tissue from each group of rats (SDC, n = 4; SD-RSV, n = 4; Ren2-C, n = 4; Ren2-RSV, n = 4) was used to evaluate nephrin with 2 antibodies (N-20 and C-17); total protein was stained with amido-black staining to normalize the data.

**Measurement of NADPH Oxidase Activity**

NADPH oxidase activity was determined in plasma membrane fractions from each group of rats (SDC, n = 6; SD-RSV, n = 4; Ren2-C, n = 6; Ren2-RSV, n = 4) and podocyte cell lysates.13–17

**Light Microscopy**

Harvested kidney cortical tissue from each group of rats (SDC, n = 4; SD-RSV, n = 4; Ren2-C, n = 4; Ren2-RSV, n = 4) were stained with Verhoeoff-van Gieson, which is specific for fibrosis and stains elastin (black), nuclei (blue black), collagen (red), and connective tissue (yellow).14,15,19

**Podocyte Cell Culture**

Details of cell culture are available in the data supplement. Briefly, a dose-response curve was established for Ang II stimulation of NADPH oxidase activity in podocyte cell lysates using a time-dependency assay, and rosuvastatin inhibition was based on previous experiments.17 In addition, superoxide generation in podocyte cell lysates was evaluated using oxidative fluorescent dihydroethidium staining.17

**RNA Extraction and Subunit Expression by Real-Time PCR**

Details of the determination of RNA extraction from podocyte cell lysates are available in the data supplement. RNA was extracted from podocytes using RNeasy Mini kits (Qiagen), and 100 ng of starting cDNA was used for Real-Time PCR with the following primers: p22phox and NOX4, gp91phox (NOX2; 5'-CCA ACT GGT ATG AGT trichloroacetic acid (TCA)-3') and reverse (5'-GAG AGT TTC AGC CAA GGC TTC-3') and Rac1.20 Expression levels were normalized using 18S as the control.

**Statistical Analysis**

All of the values are expressed as mean±SE. Statistical analyses were performed in SPSS 13.0 (SPSS Inc) using ANOVA with Fisher’s least significant difference as appropriate and Student’s t test for paired analysis. Significance was accepted as P<0.05.

**Results**

**Effect of Rosuvastatin on SBP and Albuminuria**

As measured at the end of the treatment period, there were increases in SBP in Ren2 (207.4 ± 1.3 mm Hg) when compared with SD controls (156.0 ± 9.8 mm Hg; P<0.05) without reductions in rosuvastatin-treated animals (202 ± 4.5 mm Hg and 159.7 ± 9.7 mm Hg, respectively; Figure 1A). Albuminuria was increased in the Ren2 rats at 5 weeks (0.15 ± 0.05 mg/mg), 7 to 8 weeks (0.33 ± 0.05 mg/mg), and significantly at 9 weeks (0.47 ± 0.08 mg/mg; P<0.05) when compared with SD controls at 5 weeks (0.12 ± 0.02 mg/mg), 7 to 8 weeks (0.14 ± 0.04 mg/mg), and 9 weeks (0.11 ± 0.01 mg/mg; Figure 1B). There were improvements in the rosuvastatin-treated Ren2 rats at 5 weeks (0.17 ± 0.03 mg/mg), 7 to 8 weeks (0.18 ± 0.04 mg/mg), and significantly at 9 weeks (0.26 ± 0.04 mg/mg; P<0.05).

**Effect of Rosuvastatin on Glomerular Remodeling**

Glomerular filtration barrier structural integrity was measured by TEM and light microscopy with Verhoeoff-van Gieson and nephrin immunostaining. TEM images at 10 000 and 60 000 (Figure 2A) were used to evaluate 4 criteria for...
filtration barrier integrity as described above. Significant changes in all 4 of the variables were observed when comparing Ren2 to SD glomeruli, and these changes were attenuated with rosuvastatin treatment (Figure 2B).

There were fewer slit-pores in Ren2 rats (4.3 ± 0.2 slit pores/100 μm; *P < 0.05) versus SD control rats (5.0 ± 0.1 slit pores/100 μm), improved with rosuvastatin treatment in Ren2 and SD rats (5.1 ± 0.1 and 5.8 ± 0.1 slit pores per 100 μm, respectively; each *P < 0.05; Figure 2B). Similarly, slit-pore diameter was less in Ren2 glomeruli (25.0 ± 1.5 nm) than in SD (34.3 ± 1.3 nm; **P < 0.05). However, rosuvastatin treatment did not improve slit-pore diameter in the Ren2 or SD rats (23.9 ± 1.9 nm and 29.3 ± 2.5 nm, respectively; each *P < 0.05). Increases in podocyte foot process base width paralleled the loss of the slit-pore number and diameter in the Ren2 rats (208.2 ± 9.7 nm) when compared with SD controls (159.6 ± 5.5 nm) that improved with rosuvastatin treatment in both Ren2 and SD rats (140.6 ± 4.9 nm and 131.8 ± 5.7 nm, respectively; each *P < 0.05). Interestingly, basement membrane thickness was not greater in the Ren2 (98.7 ± 1.9 nm) when compared with SD (95.3 ± 2.6 nm) glomeruli (**P < 0.05), with no rosuvastatin treatment effect in either Ren2 or SD rats (102.6 ± 2.9 nm and 99.9 ± 5.9 nm; each *P < 0.05).
There were attendant decreases in nephrin by immuno-staining and Western analysis in the Ren2 rats (19.5/11006 1.6 average grayscale intensities; 0.24/11006 0.07 arbitrary units) when compared with SD controls (27.9/11006 4.5 average grayscale intensities; 0.431/11006 0.090 arbitrary units; each P<0.05) with a trend to improvement in the rosuvastatin-treated Ren2 rats (21.7/11006 3.6 average grayscale intensities and 0.32/11006 0.04; each P<0.05; Figure S1A through S1E).

To evaluate the effects of rosuvastatin on glomerular remodeling, we morphometrically evaluated periarteriolar fibrosis in Verhoeff-van Gieson–stained sections of the kidney. There was substantial periarteriolar fibrosis in the adventitia of Ren2 rats (0.65/11006 0.01% area fibrosis) when compared with SD controls (0.39/11006 0.01% area fibrosis; P<0.05) that was improved in the rosuvastatin-treated Ren2 rats (0.41/11006 0.01% area fibrosis; P<0.05; Figure S2A and S2B). Interestingly, there were decreases in the percent area in the media of the Ren2 rats (0.28/11006 0.01% area) compared with SD controls (0.45/11006 0.01% area; P<0.05), which improved in the rosuvastatin-treated Ren2 rats (0.47/11006 0.01% area; P<0.05).

**Effect of Ang II and Rosuvastatin on NADPH Oxidase Activity and Subunits**

There were expected increases in NADPH oxidase activity in the Ren2 controls (80.9/11006 0.1 mOD/mg per minute) when compared with SD controls (67.9/11006 0.2 mOD/mg per minute; P<0.05) that improved with rosuvastatin treatment in the Ren2 rats (57.1/11006 0.1 mOD/mg per minute; P<0.05; Figure 3A). Similarly, there were dose-dependent increases in Ang II stimulation of NADPH oxidase activity in podocytes with a maximum occurring at 10 nm (Figure 4A). The increase in NADPH oxidase activity induced with 10 nM of Ang II (1.15/11006 0.03 mOD/mg per minute; P<0.05) was completely prevented with rosuvastatin treatment (0.94/11006 0.04 mOD/mg per minute; P<0.05; Figure 4B).

Similar to enzyme activity, there were increases in NADPH oxidase subunits in the kidney cortex of the Ren2 rats and in podocytes. There were increases in NOX2 and Rac in the Ren2 rats (23.5/11006 1.4 and 54.9/11006 10.9 average grayscale intensities, respectively; each P<0.05) compared with SD controls (19.6/11006 1.5 and 31.7/11006 3.6 average grayscale intensities, respectively; each P<0.05) improved with rosuvastatin treatment (18.1/11006 2.1 and 27.2/11006 4.0 average grayscale intensities, respectively; each P<0.05; Figure 3B and 3C). Similarly, increases were seen in podocytes with Ang II stimulation of NOX2 and Rac mRNA expression (3.75/11006 1.30 and 3.34/11006 0.76 average grayscale intensities, respectively; each P<0.05) relative to controls that were reversed with rosuvastatin (0.71/11006 0.08 and 1.16/11006 0.30 average grayscale intensities, respectively; Figure 4D). There were similar increases in mRNA expression of NOX4 and p22 in podocytes after Ang II stimulation (3.09/11006 0.61 and 2.79/11006 0.68 average grayscale intensities relative to control, respectively; each P<0.05) reversed with rosuvastatin treatment (1.17/11006 0.30 and 0.99/11006 0.23 average grayscale intensities, respectively; each P<0.05; Figure 4D).
Effect of Ang II and Rosuvastatin on Oxidative Stress Markers

To ascertain whether rosuvastatin affects oxidative stress, we measured 3-nitrotyrosine as a marker of peroxynitrite formation in the Ren2 and dihydroethidium in podocytes as a marker of superoxide anion generation. Kidney tissue nitrotyrosine content was increased in the Ren2 (26.3±1.7 average grayscale intensities) when compared with SD rats (12.9±1.4 average grayscale intensities; *P<0.05) reversed with rosuvastatin treatment in the Ren2 rats (15.4±1.1 average grayscale intensities; *P<0.05; Figure S3A and S3B). Similarly, there were increases in superoxide anion generation after Ang II stimulation (24.5±4.6 average grayscale intensities; *P<0.05) that were reversed with rosuvastatin (35.4±4.8 average grayscale intensities; *P<0.05; Figure S3C and S3D).

Discussion

This investigation addressed the impact of HMG-CoA reductase inhibitors (statins) on NADPH oxidase activation and subunit expression, oxidative stress, and resultant glomerular filtration barrier and podocyte injury. Filtration barrier/podocyte integrity was evaluated in the transgenic Ren2 rat, an animal model with the mouse renin transgene and RAS activation, shown previously to demonstrate enhanced renal tissue oxidative stress and albuminuria.12,19 Data from the current investigation indicate that statin therapy has renoprotective effects, as demonstrated by reductions in albuminuria,
oxidative stress, and improvements in filtration barrier indices, as well as basement membrane thickening and podocyte foot process effacement. Findings from this study are consistent with our previous findings in the heart and other reports that statins decrease NADPH oxidase–related ROS species generation through inhibition of cytosolic small-molecular-weight G proteins, such as Rac, and the membrane subunits of NADPH oxidase.14,18,21

The filtration barrier is composed of endothelium, basement membrane, and visceral epithelial cells called podocytes. Increasing evidence supports podocyte regulation of various glomerular functions, including basement membrane turnover, maintenance of the filtration barrier, regulation of the ultrafiltration coefficient, and mechanical support of the glomerular tuft.22 Intraglomerular capillaries are continuously exposed to elevated hydrostatic pressure gradients and are susceptible to the effects of NADPH oxidase activation and oxidative stress.21,23 Thus, the findings of periarteriolar and glomerular fibrosis, in addition to podocyte foot-process effacement, independent of changes in the basement membrane, in an animal model of NADPH oxidase activation support a role for ROS-mediated podocyte injury and albuminuria. Furthermore, the reductions in fibrosis and foot-process effacement with in vivo statin therapy suggest a role for statin reductions in NADPH oxidase and ROS. This supports the notion that statins may exert a renoprotective effect in maintaining the integrity of the podocyte and filtration barrier.

In the present study, the Ren2 rat demonstrated increases in NADPH oxidase activity, subunit expression, and oxidative stress in conjunction with podocyte remodeling/effacement and loss of the slit-pore diaphragm integrity. NADPH oxidase activation was accompanied by downregulation of nephrin, an important protein necessary for maintenance of podocyte slit-pore diaphragm integrity.22–24 The loss of nephrin, in turn, contributed to effacement of podocytes and loss of integrity of the slit-pore diaphragm, both requisites for progression of albuminuria.23–25 Indeed, these changes occurred in the absence of basement membrane thickening, suggesting the paramount importance of changes in slit-pore integrity in the pathogenesis of albuminuria.

In parallel with increased NADPH oxidase activity, there was an increase in peroxynitrite formation, as measured by nitrotyrosine staining in Ren2 kidneys, significantly reduced by statin therapy. NADPH oxidase catalyzes the 1-electron reduction of molecular oxygen to superoxide anion, which can react to form short-lived peroxynitrite. Peroxynitrite then forms stable 3-nitrotyrosine–conjugated molecules.14 Indeed, nitrotyrosine staining and accompanying fibrosis were particularly pronounced in the glomerulus. Oxidative stress is a known stimulus for fibrosis; ROS formation can activate redox-sensitive transcription factors, such as nuclear factor-κB, which promotes collagen and other connective tissue deposition. The current observation that in vivo statin treatment significantly decreases NADPH oxidase activity and ROS levels in concert with decreases in albuminuria and periarteriolar and glomerular fibrosis is the first such report. Moreover, benefits of rosuvastatin treatment were independent of any effects on basement membrane thickness or blood pressure.

Data in cultured podocyte cells complement our ex vivo data demonstrating that Ang II stimulates NADPH oxidase with resultant superoxide anion generation and reversed with statin treatment. Previous work suggested a role for ATP-dependent NADPH subunits p22phox, p40phox, p47phox, and NOX2 in human podocytes.26 Our data further define a role for NOX4 in the rodent podocyte. NOX4 is a homologue of NOX2 and has been defined previously in the endothelium,27 and recent immunohistochemical data support a role for NOX4 in renal mesangial cell injury in db/db diabetic mice.28

Current data further indicate that the NOX4 homologue is a critical component of the functional membrane NADPH oxidase enzyme in rodent podocytes and that statin treatment reduces the expression of this subunit in concert with attenuation of podocyte injury.

**Perspectives**

In summary, data from this investigation support a role for activation of NADPH oxidase with resultant oxidative stress and associated loss of glomerular filtration barrier/podocyte integrity, processes that are reversed with statin treatment, suggesting a potential renoprotective effect. These salutary effects of statin treatment in this investigation were mediated independent of effects on glomerular basement membrane thickening. However, in interpreting the results of this or any study that investigates blood pressure–mediated effects, measurement of SBP can be susceptible to large variability without a time course determination.

**Acknowledgments**

The immortalized murine podocyte cell line was kindly provided by Dr Peter Mundel at Mount Sinai School of Medicine. Special thanks go to Charles Wiedmeyer, DVM, PhD, and Matthew Morris for technical assistance. We also acknowledge support from the electron microscope core facility and Cheryl Jensen (electron microscopy specialist) for help with preparation of the transmission electron micrographs.

**Sources of Funding**

This research was supported by National Institutes of Health grants R01 HL73101-01A1 (to J.R.S.) and P01 HL-51952 (to C.F.), the Veterans Affairs Merit System (0018; to J.R.S.), and an investigator-initiated grant from AstraZeneca.

**Disclosures**

None.

**References**


Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin Treatment

Adam Whaley-Connell, Javad Habibi, Ravi Nistala, Shawna A. Cooper, Poorna R. Karuparthi, Melvin R. Hayden, Nathan Rehmer, Vincent G. DeMarco, Bradley T. Andresen, Yongzhong Wei, Carlos Ferrario and James R. Sowers

Hypertension. 2008;51:474-480; originally published online January 2, 2008; doi: 10.1161/HYPERTENSIONAHA.107.102467

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/51/2/474

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2007/12/18/HYPERTENSIONAHA.107.102467.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/
MS TITLE: CHBPR - Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling with Statin Treatment

Adam Whaley-Connell, DO, MSPH1,3,4, Javad Habibi, PhD1,3, Ravi Nistala, MD1,3, Shawna A. Cooper, MS1,3, Poorna R Karuparthi, MD1,3, Melvin R Hayden, MD1,3, Nathan Rehmer1,3, Vincent G DeMarco, PhD1,3, Bradley T Andresen, PhD1,3, Yongzhong Wei, MD1,3, Carlos Ferrario, MD5, James R Sowers, MD1,2,3,4

University of Missouri School of Medicine Department of Internal Medicine1, Medical Pharmacology and Physiology2, Diabetes and Cardiovascular Lab3, and Harry S Truman VA Medical Center4, and Wake Forest University School of Medicine5

Running title: Angiotensin II, NADPH Oxidase, and the Podocyte

Funding: This research was supported by NIH (R01 HL73101-01A1) (JRS) and (P01 HL-51952) (CF), the Veterans Affairs Merit System (0018) (JRS), and Investigator Initiated Grant from AstraZeneca

Corresponding Author:
Adam Whaley-Connell, DO, MSPH
Assistant Professor of Medicine
University of Missouri-Columbia School of Medicine
Department of Internal Medicine, Division of Nephrology
MA436, DC043.0
One Hospital Dr
Columbia, MO 65212
Phone(573)882-7992
Fax(573)884-4820
whaleyconnella@health.missouri.edu
Expanded Methods

Animals and treatments:

All animal procedures were approved by the institutional animal care and use committees at The University of Missouri, Harry S. Truman VA Medical Center and housed in accordance with NIH guidelines. Ren2 (5 to 6 week old) and age-matched SD male rats were randomly assigned to placebo treated control (Ren2-C and SD-C, respectively) (n=6 each) or rosvastatin (AstraZeneca) treatment groups (Ren2-RSV and SD-RSV) (n=4 each). Rosuvastatin (20 mg/kg/day) in saline or an equal volume of saline was administered in vivo intra-peritoneally (IP) to the rosvastatin or control groups, respectively for 21 days.

Systolic Blood Pressure (SBP) and Albuminuria:

SBP was determined at the end of treatment using the tail-cuff method (Harvard Systems, Student Oscillometric Recorder) three-times for 10-15 minutes after acclimatization and restraint conditioning for 48 hours at the end of treatment on days 19 or 20 (1-4). Urine albumin was determined as previously described (1).

Transmission Electron Microscopy (TEM) Methods:

Kidney cortical tissue was thinly sliced, placed immediately in primary EM fixative, and prepared as previously described (1,3,5). A JOEL 1200-EX transmission microscope was utilized to view all renal samples. Three glomeruli per rat were evaluated with five 10k and 60k images per glomeruli. TEM images were analyzed using ImageJ, (public domain, NIH) and analysis was adapted from previous work (1,3,5,6). 10k images were used to analyze the number of slit pores per 100 µm of glomerular basement membrane. Straight basement membrane with uniform thickness and upright
podocyte foot processes were used to rule out bias sample cuts. 100 µm was calibrated using the image legend and randomly placed on a straight glomerular basement membrane to measure the number of slit pores. 60k images were used to measure the slit pore diameter, the basement membrane thickness and foot process base width. Five measurements were performed for each variable per image.

**Immunofluorescent Studies:**

Harvested kidney cortical tissue was immersed and fixed in 3% paraformaldehyde and prepared as previously described (2-4). Blocks were sectioned and incubated with 1:100 dilution of primary antibodies in 10 fold diluted blocking agent, and third/fourth sections were washed and kept in the blocker. Over the course of 48 hours, a fifth, sixth, and seventh section was incubated with 1:100 nephrin C-17 (Santa Cruz, Santa Cruz, CA), 1:100 goat gp91phox (NOX2) (Santa Cruz), 1:100 mouse Rac1 antibody (Upstate Cell Signaling) respectively, in 10 fold diluted blocker. Other sections were incubated with 1:300 Alexa fluor rabbit anti-goat 647 (Molecular Probe, Eugene, OR) for NOX2, goat anti-mouse for Rac, and rabbit anti-goat for Nephrin in 10 fold diluted blocker except the sixth, which was stained with 1:300 of Alexa fluor goat anti-mouse 647 for 4 hours and examined using a laser confocal scanning microscope, images captured by using Laser-sharp software (Bio-Rad), and signal intensities measured with MetaVue software. To assess 3-nitrotyrosine content, kidney cortical tissue sections were de-paraffinized, rehydrated, and epitopes were retrieved in citrate buffer as previously described (2,3,5).

**Western Blot Analysis:**
Kidney cortical tissue was homogenized using a glass-on-glass Dounce homogenizer in sucrose homogenization buffer and centrifuged at 1,000 g to remove connective tissue. Protein concentrations were measured by OPA as above. 60 µg of the supernatants were analyzed via SDS-PAGE under reducing conditions on a 7% gel. The protein was transferred to a polyvinylidene difluoride (PVDF) membrane and blocked in 5% milk in TBST for 30 min. Two nephrin antibodies (Santa Cruz, N-20 and C-17) were used at 1:1000 combined to detect nephrin; an anti-goat HRP linked secondary antibody (1:5000) was used to visualize nephrin via film. The film was scanned into a computer and band density was determined using ImageJ. Total protein was stained with amido-black staining, which was used to normalize the nephrin data.

Measurement of NADPH Oxidase Activity:

NADPH oxidase activity was determined in plasma membrane fractions as previously described (3,4,7).

Light Microscopy:

Harvested kidney cortical tissue were stained with VVG (Verhoeff-van Gieson); which is specific for fibrosis and stains elastin (black), nuclei (blue black), collagen (red), and connective tissue (yellow) as previously described (2,3,5).

Podocyte Cell Culture:

Immortalized murine podocyte cells obtained from Peter Mundel, PhD, Mount Sinai School of Medicine, were cultured as previously described (7). A dose response curve was established for Ang II stimulation of NADPH oxidase activity using a time dependency assay and rosuvastatin inhibition was based on previous experiments (7). Preparation and protocols for incubations have been previously described (7). All
cellular assays were normalized to total protein content, determined via Bradford assay. Superoxide \( (O_2^-) \) generation in podocytes were evaluated by using oxidative fluorescent dihydroethidium (DHE) staining as previously described (7).

**RNA extraction and subunit expression by Real-Time PCR:**

Podocytes were grown, differentiated, starved overnight and treated with Ang II (10nM) or Ang II + rosuvastatin (10uM) as described above. RNA was extracted from podocytes using RNeasy Mini Kits (Qiagen, Germany). The integrity of extracted RNA was assessed visually following separation of samples on a formaldehyde gel. A ratio of 2:1 for 28S:18S was considered satisfactory. In addition, ratios of \( A_{260}/A_{280} \) of 2.0 or better indicated samples had minimal protein contamination. Samples were DNase1 treated with reagents from Invitrogen (Carlsbad, CA) and cDNA prepared using Taqman Reverse Transcription Reagents from Applied Biosystems (Foster City, CA). 100ng of starting cDNA was used for Real-Time PCR with the following primers: p22\textsubscript{phox} and NOX4, gp91\textsubscript{phox} (NOX2) (5'-CCA ACT GGG ATA ACG AGT TCA-3') and Reverse (5'-GAG AGT TTC AGC CAA GGC TTC-3') and Rac1 (8). Universal Real Time cycling parameters were used with the following exceptions: annealing temp of 70C for p22\textsubscript{phox} and NOX4, SybrGreen system for p22\textsubscript{phox}, Nox4, Rac1 and NOX2 and Taqman Universal Master Mix for 18S primer/probe set. Expression levels were normalized using 18S as control. 18S levels did not change with treatments. In order to account for day-to-day and plate-to-plate variations, increases or decreases in transcript level were expressed relative to the mean of the SD control group. Measurements of fold changes were done using standard curve method.

**Statistical Analysis:**
All values are expressed as mean ± standard error. Statistical analyses were performed in SPSS 13.0 (SPSS Inc., Chicago IL) using ANOVA with Fisher’s LSD as appropriate and student’s t-test for paired analysis. Significance was accepted as p<0.05.

**Funding:** This research was supported by NIH (R01 HL73101-01A1) (JRS) and (P01 HL-51952) (CF), the Veterans Affairs Merit System (0018) (JRS), and Investigator Initiated Grant from AstraZeneca

**References**


**Figure S1: Decreased Nephrin in Transgenic Ren2 rats.** A) Immunostaining of nephrin (C-17) and 4',6-diamidino-2-phenylindole (DAPI). B) Fluorescent images from panel A were merged with the transmitted images showing the glomerular structure. C) Monostaining of the paraffin embedded kidney sections of different animals which were
captured by different system for quantification of nephrin expression in the glomerular area of different treatments. D) Western analysis of nephrin. E) Average gray scale intensities measures of panel C, showing significantly smaller number in Ren2C animals. (scale bar = 50 µM) *, p <0.05 when Ren2 controls (Ren2-C) (n=4) are compared to age-matched Sprague-Dawley controls (SD-C) (n=4). (n=4 for rosuvastatin treated SD and Ren2 groups).

**Figure S2:** Rosuvastatin attenuation of Peri-Arteriolar Remodeling in the Transgenic Ren2 rat. (A) Representative images of Verhoeff-van Gieson (VVG), specific for fibrosis, stained sections of arterioles in kidney cortical tissue. (B) Representative images of glomeruli with increases in periglomerular and glomerular staining observed in the Ren2 control. (C) Average calculated values of percentage area of adventitia, media and the lumen of the intramural arteries in the heart. (scale bar=50 µM) *, p <0.05 when Ren2 controls (Ren2-C) (n=4) are compared to age-matched Sprague-Dawley controls (SD-C) (n=4). **, p <0.05 when rosuvastatin treated Ren2 rats (Ren2-RSV) (n=4) or SD (SD-RSV) (n=4) are compared to age-matched controls.

**Figure S3:** Rosuvastatin improves Oxidative Stress. (A) 3-nitrotyrosine immunostaining as a marker of peroxynitrite formation in the transgenic Ren2 rat. (B) Grey scale intensity measures of panel A. (scale bar = 50 µM) *, p <0.05 when Ren2 controls (Ren2-C) (n=4) are compared to age-matched Sprague-Dawley controls (SD-C) (n=4). **, p <0.05 when rosuvastatin treated Ren2 rats (Ren2-RSV) (n=4) or SD (SD-RSV) (n=4) are compared to age-matched controls. (C) Dihydroethidium immunostaining
as a marker of superoxide anion formation in podocyte cell culture (n=4). *, p<0.05 when compared to control; **, p <0.05 when compared to angiotensin II stimulation alone.
Figure S1

A: SD-C  SD-RSV  Ren2-C  Ren2-RSV

B: SD-C  SD-RSV  Ren2-C  Ren2-RSV

C: SD-C  SD-RSV  Ren2-C  Ren2-RSV

D:

[Graph showing arbitrary units for average gray scale intensities]

* indicates a significant difference between groups.
Figure S2

A:

SD-C

Ren2-C

B:

SD-C

Ren2-C

SD-RSV

Ren2-RSV

Perivascular Fibrosis

Normalized Area

- Adventitia
- Media
- Lumen

* * **

A: SD-C

Ren2-C

SD-RSV

Ren2-RSV

**

B: SD-C

Ren2-C

SD-RSV

Ren2-RSV
Figure S3

A: SD-C SD-RSV
Ren2-C Ren2-RSV

B: Average Grey Scale Intensities

C: Control Ang II Ang II + RSV

D: Average Grey Scale Intensities